Duchenne氏肌肉失養症市場規模、佔有率、成長分析、按類型、按治療類型、按診斷、按最終用戶、按地區 - 行業預測，2025-2032 年

2023年，全球Duchenne氏肌肉失養症市場規模為21億美元，從2024年的23.4億美元成長到2032年的56.4億美元，複合年成長率預計將成長11.6%。

隨著研究和開發力度加大，尋找針對這種主要影響男性的罕見遺傳疾病的可行治療方法，全球Duchenne氏肌肉失養症(DMD) 市場預計將會成長。 DMD 的特徵是進行進行性肌肉無力，可導致智力低下、呼吸衰竭和心臟併發症等嚴重併發症。目前的治療方法，如類固醇藥物、幹細胞療法和基因療法，旨在緩解症狀，但尚無治療方法。肌肉萎縮症協會在這一領域做出了重大貢獻，最近資助了 75,000 美元用於治療 DMD 的研究，超過 150 個醫療機構獲得了津貼。對基因編輯、外顯子跳躍和幹細胞應用等創新治療的日益關注預計將進一步推動 DMD 治療市場的發展。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 宏觀經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究

Duchenne氏肌肉失養症市場規模：依類型

• 市場概況
• Duchenne氏肌肉失養症(DMD) 1 型
• Duchenne氏肌肉失養症(DMD) 2 型
• 其他

按治療類型分類的Duchenne氏肌肉失養症市場規模

• 市場概況
• 基因治療
• 類固醇
• 外顯子跳躍
• 抗發炎藥
• 酵素替代療法
• 其他

Duchenne氏肌肉失養症市場規模：依診斷分類

• 市場概況
• 基因檢測
• 肌肉切片檢查
• 肌電圖（EMG）
• 影像技術（MRICT掃描）
• 血液檢查（CPK值等）

Duchenne氏肌肉失養症市場規模：依最終用戶分類

• 市場概況
• 醫院
• 專科診所
• 居家護理
• 診斷實驗室

依給藥途徑分類的Duchenne氏肌肉失養症市場規模

• 市場概況
• 口服
• 可注射的
• 話題

Duchenne氏肌肉失養症市場規模：按分銷管道

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

Duchenne氏肌肉失養症市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Mylan NV（US）
• Fresenius Kabi AG（Germany）
• Hikma Pharmaceuticals plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol Myers Squibb Company（US）
• GSK plc（UK）
• Bayer AG（Germany）
• Sun Pharmaceutical Industries Ltd.（India）
• Boehringer Ingelheim（Germany）
• Sanofi（France）
• Sarepta Therapeutics, Inc.（US）
• Aurobindo Pharma（India）
• Capricor Therapeutics, Inc.（US）
• Catalyst Pharmaceuticals Inc（US）
• EspeRare Foundation（Switzerland）
• FibroGen, Inc.（US）
• Italfarmaco SpA（Italy）

結論和建議

Global Duchenne Muscular Dystrophy Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.34 billion in 2024 to USD 5.64 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

The global Duchenne muscular dystrophy (DMD) market is poised for growth as research and development efforts intensify to discover viable treatments for this rare hereditary condition, predominantly affecting males. DMD is characterized by progressive muscle weakness and can lead to serious complications such as mental retardation, respiratory failure, and heart complications. Current management approaches, including steroid medications, stem cell therapy, and gene therapy, aim to alleviate symptoms, although no cure exists. The Muscular Dystrophy Association has contributed significantly to this sector, recently funding $75,000 towards research for DMD treatments, with over 150 healthcare institutions receiving grants. Increased focus on innovative therapies such as gene editing, exon skipping, and stem cell applications is expected to further propel the DMD treatment market forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Duchenne Muscular Dystrophy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Duchenne Muscular Dystrophy Market Segmental Analysis

Global Duchenne Muscular Dystrophy Market is segmented by Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Duchenne Muscular Dystrophy (DMD) Type 1, Duchenne Muscular Dystrophy (DMD) Type 2 and Others. Based on Treatment Type, the market is segmented into Gene Therapy, Steroids, Exon Skipping, Anti-inflammatory Drugs, Enzyme Replacement Therapy and Others. Based on Diagnosis, the market is segmented into Genetic Testing, Muscle Biopsy, Electromyography (EMG), Imaging Techniques (MRI, CT scan) and Blood Tests (CPK Levels, etc.). Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Home Care and Diagnostic Laboratories. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Duchenne Muscular Dystrophy Market

The global Duchenne Muscular Dystrophy (DMD) market is experiencing significant growth driven by the increasing prevalence of the disorder. Key factors propelling this market include heightened awareness initiatives regarding DMD, the emergence of mutation-specific treatments, and a growing pipeline of therapeutic options. Breakthroughs such as Exondys51 and Translarna, along with corticosteroid-based anti-inflammatory therapies, further contribute to this expansion. Additionally, factors such as rising healthcare costs in developed nations and improved medical reimbursement options enhance market accessibility. The persistent unmet need for effective DMD treatments offers considerable opportunities for market players, prompting numerous companies to initiate clinical trials for innovative therapies.

Restraints in the Global Duchenne Muscular Dystrophy Market

The global Duchenne muscular dystrophy (DMD) market is expected to face significant obstacles, primarily stemming from challenges related to late diagnosis and reduced patient engagement due to prognosis uncertainties. Tracking the effectiveness of DMD treatments is complicated by the requirement for various outcome measures at different disease stages, many of which lack both sensitivity and objectivity. For instance, the widely utilized six-minute walk test can only be administered to ambulant DMD patients aged five and above, necessitating extensive cohorts and time to ascertain meaningful benefits. Moreover, the absence of appropriate outcome measures often leads to the exclusion of very young children and non-ambulant patients from clinical trials, further hindering market growth for DMD treatments.

Market Trends of the Global Duchenne Muscular Dystrophy Market

The global Duchenne muscular dystrophy (DMD) market is witnessing a significant upward trend, propelled by the emergence of innovative pharmaceuticals and disease-modifying therapies. This growth is further bolstered by substantial investments from various pharmaceutical companies dedicated to DMD research, alongside effective collaborations with patient advocacy groups that play a crucial role in fostering regulatory approval processes. As awareness and understanding of DMD enhance, the market is expected to expand, with an increased focus on personalized treatments and gene therapy advancements. This dynamic landscape indicates a promising future for stakeholders involved in DMD care and management, as they strive to address unmet medical needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Duchenne Muscular Dystrophy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Duchenne Muscular Dystrophy (DMD) Type 1
• Duchenne Muscular Dystrophy (DMD) Type 2
• Others

Global Duchenne Muscular Dystrophy Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Gene Therapy
• Steroids
• Exon Skipping
• Anti-inflammatory Drugs
• Enzyme Replacement Therapy
• Others

Global Duchenne Muscular Dystrophy Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Genetic Testing
• Muscle Biopsy
• Electromyography (EMG)
• Imaging Techniques (MRI, CT scan)
• Blood Tests (CPK Levels, etc.)

Global Duchenne Muscular Dystrophy Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Home Care
• Diagnostic Laboratories

Global Duchenne Muscular Dystrophy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Duchenne Muscular Dystrophy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Duchenne Muscular Dystrophy Market Size & CAGR (2025-2032)

• North America (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Pharmaceuticals Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EspeRare Foundation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Italfarmaco S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations